BioSpace News Archive

Called “female Viagra” in the media, Ovoca Bio’s BP-101 (Libicore) nasal spray therapy for low libidos in premenopausal women is undergoing Phase II trials.

VIATRIS (acquired by Meda AB) (NASDAQ: VTRS) today reported results for the second quarter of 2021, highlighted by strong performance across the entire business and substantial cash flow generation.

Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the appointment of Jane Chung to the newly-created position of Chief Commercial Officer, effective August 9, 2021.

Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ platform, announced that Kara Bickham, MD, has joined the company as Chief Medical Officer.

Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported its financial results for the quarter ended June 30, 2021, its recent business highlights, and provided a preview of anticipated selected milestones in the second half of 2021.

Antibe Therapeutics Inc. today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 - 12.

Brings leadership experience from Agios Pharmaceuticals and Novartis Vaccines with strategy and operations expertise across many stages of product development and company growth

Agenus Inc. today provided a corporate update and reported financial results for the second quarter of 2021.

Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases and sustained-release drug delivery systems, announced it has been awarded a second grant from the Bill & Melinda Gates Foundation.

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021.